Key Takeaways
- HGS BioScience, backed by Paine Schwartz Partners, has acquired Idaho-based Pharmgrade, a specialist in microbial consortium products, to strengthen its biological crop solutions offering.
- The acquisition builds on the late-2025 combination of HGS BioScience and NutriAg, advancing the company’s strategy to create a scaled, science-led biologicals platform.
- Pharmgrade adds more than 30 years of microbial development expertise, complementing HGS’s existing portfolio of humates, bionutritionals, and plant extracts.
- The combined platform is designed to help retailers and growers navigate a fragmented biologicals market with consistent, field-proven solutions.
- The company aims to leverage integrated R&D, manufacturing scale, and broad market access to deliver stacked biological technologies with measurable return on investment.
HGS BioScience Expands Platform With Pharmgrade Acquisition
Paine Schwartz Partners–backed HGS BioScience, a provider of biological crop solutions, has announced the acquisition of Pharmgrade, an Idaho-based innovator specializing in microbial consortium products. The transaction represents the next phase in HGS BioScience’s strategy to build a comprehensive biologicals platform serving agricultural retailers and growers across North America and select international markets.
The acquisition follows the successful integration of HGS BioScience and NutriAg in late 2025 and further expands the company’s technical and product capabilities in one of the fastest-growing segments of the agricultural inputs market.
HGS BioScience's Strengthening Capabilities in Microbial Technologies
Pharmgrade brings decades of experience in the development and optimization of microbial consortium products, adding depth to the company's biological portfolio. The company’s microbial expertise complements HGS’s established strengths in humates, bionutritionals, and plant extracts, enabling broader technology integration and product stacking.
